Quell Therapeutics and Cellistic™ enter a strategic collaboration
After Ncardia launched its affiliate company Cellistic last week, dedicated to making large-scale allogeneic cell therapy production a reality, they are proud to now enter a strategic collaboration with Quell Therapeutics, to develop an iPSC-derived allogeneic T-regulatory cell therapy platform.
London, UK and Gosselies, Belgium – April 27 2022 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, and Cellistic™, the iPSC-focused cell therapy process development & manufacturing partner recently launched by Ncardia to make large-scale allogeneic cell therapy production a reality, announce they have entered into a strategic collaboration for the co-development of an iPSC-derived Treg cell therapy platform. The goal of the partnership is to facilitate the future expansion of Quell’s autologous Treg cell therapy pipeline by adding off-the-shelf, allogeneic Treg cell therapy products, leveraging Cellistic™’s expertise in differentiation and scale-up of iPSC processes for allogeneic cell therapy applications.
Iain McGill, Chief Executive Officer, Quell Therapeutics, said:
Read the full press release here!